Is Peregrine Preparing to Soar Again?
In this video, health-care analyst David Williamson discusses Peregrine Pharmaceuticals' announcement and stock pop from completing enrollment of a phase 1 trial for its lead drug candidate bavituximab in breast cancer. Bavituximab has endured a lot of (clinical) trials and tribulations, including in NSCLC and pancreatic cancer, and this video puts today's news into perspective with the larger picture investors need to know.
Can Celgene continue to soar?
Every in-the-know biotech investor has an eye on Celgene. Shares have skyrocketed this year as the company outlined a plan to almost triple its profits in only a few years. But should you buy the story Celgene is selling? Make sure you understand the key opportunities and risks facing this company by picking up The Motley Fool's brand-new premium report on Celgene. To claim your copy today simply click here now.
The article Is Peregrine Preparing to Soar Again? originally appeared on Fool.com.David Williamson has no position in any stocks mentioned. Follow David on Twitter: @MotleyDavid. The Motley Fool recommends Celgene. Try any of our Foolish newsletter services free for 30 days. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.
Copyright © 1995 - 2013 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.